Drug Profile
SPD 451
Alternative Names: Dopamine D1 agonists - Takeda; SPD451Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator CeNeS Pharmaceuticals
- Developer CeNeS Pharmaceuticals; Shire Pharmaceutical Development
- Class
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 17 Jun 2004 Discontinued - Preclinical for Parkinson's disease in United Kingdom (unspecified route)
- 25 Jun 2002 This compound is still in active development with Shire Pharmaceuticals